Gian Paolo Rossi Selected Research

MDL 100240

7/2006	The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension.
4/2004	Bradykinin and matrix metalloproteinases are involved the structural alterations of rat small resistance arteries with inhibition of ACE and NEP.
1/2003	Dual ACE and NEP inhibitors: a review of the pharmacological properties of MDL 100240.
7/2002	Dual ACE and NEP inhibitor MDL-100,240 prevents and regresses severe angiotensin II-dependent hypertension partially through bradykinin type 2 receptor.
2/2002	Comparative effects of the dual ACE-NEP inhibitor MDL-100,240 and ramipril on hypertension and cardiovascular disease in endogenous angiotensin II-dependent hypertension.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gian Paolo Rossi Research Topics

Disease

82	Hyperaldosteronism (Conn Syndrome) 11/2022 - 07/2002
76	Hypertension (High Blood Pressure) 11/2022 - 02/2002
59	Adenoma (Adenomas) 01/2022 - 02/2006
13	Neoplasms (Cancer) 01/2022 - 03/2006
13	Coronary Artery Disease (Coronary Atherosclerosis) 10/2015 - 03/2003
11	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 02/2002
10	Hyperplasia 09/2019 - 04/2004
9	Hypokalemia 01/2020 - 04/2008
9	Atherosclerosis 11/2017 - 11/2003
8	Heart Failure 11/2022 - 01/2003
7	Essential Hypertension 01/2021 - 07/2008
7	Hypertrophy 06/2016 - 02/2002
6	Fibrosis (Cirrhosis) 03/2016 - 02/2003
5	Pheochromocytoma 11/2022 - 03/2006
5	Stroke (Strokes) 01/2022 - 01/2003
5	Body Weight (Weight, Body) 10/2008 - 02/2002
4	Overweight 01/2018 - 03/2003
3	Renovascular Hypertension (Goldblatt Syndrome) 11/2022 - 05/2002
3	Inflammation (Inflammations) 01/2022 - 03/2016
3	Familial Hyperaldosteronism 01/2022 - 09/2016
3	Adrenocortical Carcinoma 10/2019 - 03/2005
3	Gitelman Syndrome 08/2018 - 02/2014
3	Chronic Renal Insufficiency 01/2018 - 01/2016
3	Pre-Eclampsia (Preeclampsia) 01/2018 - 02/2013
3	Vascular Remodeling 01/2018 - 01/2003
3	Hypotension (Low Blood Pressure) 11/2015 - 04/2004
2	COVID-19 05/2022 - 01/2020
2	Myocardial Infarction 01/2022 - 05/2006
2	Left Ventricular Dysfunction 01/2022 - 01/2007
2	Hypovolemia 01/2021 - 12/2019
2	Atrial Fibrillation 11/2019 - 01/2018
2	Hyperparathyroidism 01/2019 - 08/2012
2	Channelopathies 12/2018 - 09/2014
2	Obstructive Sleep Apnea 01/2018 - 11/2016
2	Hyperhomocysteinemia 01/2018 - 04/2005
2	Airway Obstruction (Choking) 01/2018 - 10/2016
2	Renal Artery Obstruction (Renal Artery Stenosis) 04/2015 - 05/2002
2	Weight Loss (Weight Reduction) 07/2014 - 10/2013
2	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 07/2014 - 07/2002
2	Obesity 10/2013 - 03/2003

Drug/Important Bio-Agent (IBA)

79	AldosteroneIBA 01/2022 - 07/2002
25	ReninIBA 01/2022 - 05/2002
15	Angiotensin IIIBA 05/2022 - 02/2002
11	Pharmaceutical PreparationsIBA 11/2022 - 10/2003
9	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2022 - 03/2006
8	Endothelins (Endothelin)IBA 01/2022 - 01/2003
7	Antihypertensive Agents (Antihypertensives)IBA 11/2022 - 05/2008
7	Proteins (Proteins, Gene)FDA Link 01/2021 - 04/2004
6	Mineralocorticoid Receptor AntagonistsIBA 01/2022 - 10/2013
6	PotassiumIBA 01/2021 - 09/2014
6	SodiumIBA 01/2021 - 08/2007
6	Cytochrome P-450 CYP11B2 (CYP11B2)IBA 01/2021 - 12/2007
5	AngiotensinsIBA 01/2021 - 05/2002
5	MineralocorticoidsIBA 01/2021 - 09/2006
5	HomocysteineIBA 12/2008 - 01/2005
5	MDL 100240IBA 07/2006 - 02/2002
4	Hormones (Hormone)IBA 11/2022 - 01/2018
4	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 05/2022 - 07/2002
4	Type 1 Angiotensin ReceptorIBA 05/2022 - 02/2014
4	Peptides (Polypeptides)IBA 01/2021 - 05/2002
4	Messenger RNA (mRNA)IBA 01/2021 - 03/2006
4	Captopril (Capoten)FDA LinkGeneric 01/2019 - 12/2006
4	Endothelin-1 (Endothelin 1)IBA 01/2018 - 02/2002
4	Ramipril (Altace)FDA LinkGeneric 07/2006 - 02/2002
4	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 09/2004 - 03/2003
3	Cosyntropin (Cortrosyn)FDA LinkGeneric 03/2020 - 01/2017
3	AutoantibodiesIBA 10/2019 - 02/2013
3	AcidsIBA 01/2018 - 04/2014
3	AntioxidantsIBA 11/2015 - 01/2013
3	EnzymesIBA 11/2015 - 11/2003
3	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 10/2015 - 01/2012
3	oxidized low density lipoproteinIBA 06/2014 - 10/2003
3	LDL Lipoproteins (beta Lipoproteins)IBA 09/2013 - 11/2003
3	Adrenocorticotropic Hormone (ACTH)FDA Link 05/2009 - 02/2006
3	AdiponectinIBA 10/2008 - 06/2006
3	Irbesartan FDA LinkGeneric 10/2008 - 07/2002
3	CollagenIBA 02/2003 - 07/2002
2	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 11/2015
2	NormetanephrineIBA 01/2022 - 10/2021
2	CytokinesIBA 01/2022 - 11/2017
2	Androstenedione (4 Androstene 3,17 dione)IBA 10/2021 - 01/2017
2	olmesartanIBA 01/2020 - 01/2019
2	CanrenoneIBA 01/2020 - 01/2019
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2020 - 04/2004
2	Oxygen (Dioxygen)IBA 01/2019 - 10/2016
2	Metoclopramide (Reglan)FDA LinkGeneric 01/2018 - 11/2016
2	MacrolidesIBA 01/2018 - 12/2017
2	AntigensIBA 11/2017 - 03/2010
2	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2016 - 02/2013
2	rho-Associated KinasesIBA 01/2016 - 02/2014
2	4- ethoxymethylene- 2- phenyl- 2- oxazoline- 5- one (phOx)IBA 11/2015 - 06/2014
2	LipidsIBA 11/2015 - 10/2003
2	GTP-Binding Proteins (G-Protein)IBA 11/2014 - 02/2009
2	AntibodiesIBA 09/2013 - 11/2003

Therapy/Procedure

35	Adrenalectomy 11/2022 - 03/2002
13	Therapeutics 01/2020 - 09/2006
5	Continuous Positive Airway Pressure 01/2018 - 06/2014
3	Nephrectomy 06/2006 - 03/2002
2	Denervation 01/2022 - 07/2013
2	Catheters 01/2017 - 08/2011